UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): January 1, 2019
FOAMIX PHARMACEUTICALS LTD.
(Exact name of registrant as specified in its charter)
|
|
|
|
|
Israel
|
001-36621
|
N/A
|
|
(State or other jurisdiction
of incorporation)
|
(Commission File Number)
|
(IRS Employer
Identification No.)
|
|
|
|
|
|
|
|
2 Holzman Street,
Weizmann Science Park
|
|
|
|
|
Rehovot, Israel
|
7670402
|
|
|
|
(Address of principal executive offices)
|
(Zip Code)
|
|
|
|
|
+972-8-9316233
|
|
(Registrant’s telephone number, including area code)
|
|
(Former name or former address, if changed since last report)
|
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
☐ Written communications pursuant to
Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to
Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐ Pre-commencement communications pursuant to
Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐ Pre-commencement communications pursuant to
Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company
☒
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
☒
Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
The board of directors of Foamix Pharmaceuticals Ltd. (the “Company”) determined that effective January 1, 2019, Yohan Hazot, Vice President, Pharmaceutical Development and a named executive officer of the Company, is no longer an “executive officer” of the Company within the meaning of Rule 3b-7 of the Securities Exchange Act of 1934, as amended. Mr. Hazot will retain his current title of Vice President, Pharmaceutical Development and continue in the Company’s employ.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date: January 3, 2019
|
|
FOAMIX PHARMACEUTICALS LTD.
|
|
|
|
|
|
|
|
By:
|
/s/ Mutya Harsch
|
|
|
|
|
Mutya Harsch
|
|
|
|
|
Chief Legal Officer
|
|